|
Volumn 27, Issue 2, 2014, Pages 271-280
|
Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy
a,b b a a a b b b b b b b b b b b b b b |
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLIN DEPENDENT KINASE INHIBITOR 2A;
DNA;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
FIBROBLAST GROWTH FACTOR RECEPTOR 1;
FIBROBLAST GROWTH FACTOR RECEPTOR 3;
FORMALDEHYDE;
PARAFFIN;
PROTEIN MCL 1;
PROTEIN MDM2;
VASCULOTROPIN RECEPTOR;
ADVANCED CANCER;
ARTICLE;
BLADDER CARCINOMA;
BLADDER TRANSITIONAL CELL CARCINOMA;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER RECURRENCE;
CANCER SURGERY;
CHROMATIN;
DISEASE SEVERITY;
DNA EXTRACTION;
EXON;
FRAMESHIFT MUTATION;
GENE IDENTIFICATION;
GENE MUTATION;
GENE REARRANGEMENT;
GENE SEQUENCE;
GENE TARGETING;
GENOMICS;
HYBRIDIZATION;
INDEL MUTATION;
INTRON;
NEXT GENERATION SEQUENCING;
NONSENSE MUTATION;
PRIORITY JOURNAL;
SEQUENCE ANALYSIS;
TRANSITIONAL CELL CARCINOMA;
TUMOR GENE;
ADULT;
AGED;
AGED, 80 AND OVER;
CARCINOMA, TRANSITIONAL CELL;
FEMALE;
HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING;
HUMANS;
MALE;
MIDDLE AGED;
SEQUENCE ANALYSIS, DNA;
URINARY BLADDER NEOPLASMS;
|
EID: 84893786820
PISSN: 08933952
EISSN: 15300285
Source Type: Journal
DOI: 10.1038/modpathol.2013.135 Document Type: Article |
Times cited : (120)
|
References (0)
|